<unk> , sold under the brand name Tivdak, is an antibody-drug conjugate used to treat cervical cancer. It is a combination of<unk> , a monoclonal antibody against tissue factor, and monomethyl auristatin E (MMAE), a potent inhibitor of cell division.<unk>  was approved for medical use in the United States in September 2021. It is administered by infusion into a vein every 3 weeks.<unk>  is the international nonproprietary name (INN).
Tisotumab vedotin
Sacituzumab govitecan
Enfortumab vedotin
Bezlotoxumab
Teprotumumab
Tralokinumab
Lanadelumab
Alirocumab